Should I buy CSL shares before 2023?

Could a dose of CSL increase the health of a stock portfolio next year?

| More on:
Two researchers discussing results of a study with each other.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The CSL share price is in the red by 2% this year
  • Some experts believe the biotech company could perform well from here
  • CSL has demonstrated an ability to generate bigger profits than its competitors in the past

Out of the five largest companies on the ASX by market capitalisation, CSL Limited (ASX: CSL) shares have performed the worst throughout 2022.

The market went cold on the biotech giant in January as the world was gripped by uncertainty. A month earlier, the company announced it intended to hand over A$17.5 billion to acquire Vifor Pharma in what would be CSL's largest deal in its history.

Fast forward to today, the CSL share price is 2.3% worse off than where it finished up last year. Could the depressed share price be a buying opportunity before 2023? Or, could it be better to avoid injecting this company into your portfolio?

What do the experts think of CSL shares?

Despite the Australian drug developer's rather lofty price-to-earnings (P/E) ratio, a number of brokers and fund managers still like the look of CSL. At the current market rate, the plasmas-derived product maker trades at 40 times earnings.

Nonetheless, the team at Citi holds a buy rating on the company's shares with a $340 price target. This would suggest an additional 17% upside from here. Part of the optimistic perspective relies on CSL's drug development pipeline — something that the Vifor acquisition is believed to further enhance.

Likewise, analysts at Bell Potter hold a positive outlook on CSL amid its latest expansion. The broker also foresees strong and sustained growth in global plasma volumes, increasing at an 8% per annum clip.

Finally, Tribeca portfolio manager Jun Bei Liu shared a bullish perspective on CSL shares a few weeks ago. Liu revealed her expectations that the biotech company will " … grow double digits for the next three years."

Why it could be worth the premium

The success of a company can be influenced by the acumen or ineptitude of its competition. That's why I would take a look at some of CSL's rivals in the industry.

A couple of competitors that come to mind are Grifols (a Spanish plasma-based pharmaceutical player) and Baxter International Inc (NYSE: BAX) (an American healthcare giant focused on areas similar to Vifor).

Of these three companies, CSL has the thickest profit margins… it's not even a close comparison. This would suggest CSL is either a superiorly managed company, holds more valuable intellectual property, operates more efficiently, or a combination of these.

After all, the CSL share price probably wouldn't be up more than 100% over the past five years if it didn't have some edge.

Motley Fool contributor Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A women has her eyes checked at the optometrist.
Healthcare Shares

Is Medibank stock a good buy?

Can this company provide healthy returns?

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX healthcare stock is jumping 7% on US FDA approval news

This share is giving its shareholders an early Christmas present.

Read more »

A senior pharmacist talks to a customer at the counter in a shop
Healthcare Shares

Is it too late to buy Sigma shares to cash in on the Chemist Warehouse deal?

Can investors still make healthy returns with this stock?

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Why the Mesoblast share price is diving 18% after an FDA win

Investors are sending the Mesoblast share price tumbling on Friday. But why?

Read more »

A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition
Healthcare Shares

Mesoblast share price rockets 30% on big US FDA news

Big news is giving this biotech a huge lift on Thursday.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

Guess which ASX healthcare stock is jumping 12% on Wednesday

This shares is rocketing this morning. But why? Let's find out.

Read more »

Man holding out Australian dollar notes, symbolising dividends.
Healthcare Shares

Here is the dividend forecast to 2029 for CSL shares

Can this blue-chip giant provide healthy dividend income?

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

The best ASX 200 healthcare stocks to buy in 2025

These shares could give your portfolio a healthy boost next year according to Bell Potter.

Read more »